Ferinject® Assessment in Patients With Iron Deficiency and Chronic Heart Failure (FAIR-HF)

Phase 3

Completed

• Conditions: Iron Deficiency; Iron Deficiency Anemia; Anaemia; Chronic Heart Failure
• Interventions: Drug: Ferinject ® (Ferric carboxymaltose); Drug: Normal saline (0.9%)

• Registration Number: NCT00520780
• Lead Sponsor: Vifor Pharma

Brief Summary

This study is designed to evaluate the efficacy of Ferinject® in improving symptoms of CHF in patients with iron deficiency. Analyses will focus both on subjective and objective measures. Furthermore, the tolerability and safety of Ferinject® treatment will be evaluated.

Detailed Description

Not available

Study Timeline

• Study Start: 2007-04
• Study First Submitted: 2007-08-24
• Study First Submitted QC: 2007-08-24
• Study First Posted: 2007-08-27
• Primary Completion: 2009-07
• Study Completion: 2009-09
• Status Verified: 2010-03
• Last Update Submitted: 2021-10-05
• Last Update Posted: 2021-10-14

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 456

Inclusion Criteria

• In New York Heart Association (NYHA) II-III functional class due to stable symptomatic chronic heart failure (CHF)
• Left ventricular ejection fraction (LVEF) 40% or lower for patients in NYHA II and 45% or lower in NYHA III
• Screening haemoglobin (Hb) at least 9.5 g/dL but below or equal to 13.5 g/dL (average of 2 haemoglobin concentrations)
• Screening ferritin below 100 µg/L, or below 300 µg/L when transferrin saturation (TSAT) is below 20%

Exclusion Criteria

• History of acquired iron overload.
• Known active infection, clinically significant bleeding, active malignancy.
• Chronic liver disease and/or screening alanine transaminase (ALT) or aspartate transaminase (AST)
• Anaemia due to reasons other than iron deficiency
• Immunosuppressive therapy or renal dialysis (current or planned within the next 6 months).
• History of erythropoietin, i.v. or oral iron therapy, and blood transfusion in previous 12 weeks and/or such therapy planned within the next 6 months.
• Unstable angina pectoris as judged by the investigator, clinically significant uncorrected valvular disease or left ventricular outflow obstruction, obstructive cardiomyopathy, poorly controlled fast atrial fibrillation or flutter, poorly controlled symptomatic brady- or tachyarrhythmias.
• Acute myocardial infarction or acute coronary syndrome, transient ischaemic attack or stroke within the last 3 months.
• Coronary-artery bypass graft, percutaneous intervention (e.g. cardiac, cerebrovascular, aortic; diagnostic catheters are allowed) or major surgery, including thoracic and cardiac surgery, within the last 3 months.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
1	Ferinject ® (Ferric carboxymaltose)	-
2	Normal saline (0.9%)	-

Primary Outcome Measures

Name	Time	Method
Self-reported patient global assessment (PGA) and NYHA functional status 24 weeks after initiation of therapy	24 weeks

Secondary Outcome Measures

Name	Time	Method
Key secondary objectives (efficacy): Exercise tolerance (6-minute walk test distance). Further secondary objectives(efficacy): Health related quality of life, resource use and costs associated with the treatment, safety and tolerability	24 weeks

Trial Locations

Locations (5)

Research Sites; 🇺🇦 Kiev, Ukraine

Research Site; 🇺🇦 Zaporozhye, Ukraine

Reserach Site; 🇷🇴 Craiova, Romania

Reserach Sites; 🇷🇺 Moscow, Russian Federation

Resarch Sites; 🇷🇺 St. Petersburg, Russian Federation